

## Datasheet: HCA331

<b>Description:</b>	HUMAN ANTI IPILIMUMAB (DRUG/TARGET COMPLEX)
<b>Specificity:</b>	IPILIMUMAB
<b>Other names:</b>	Yervoy
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD34294
<b>Isotype:</b>	HuCAL Fab monovalent
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

### Product Form

A monovalent human recombinant Fab (lambda light chain) selected from the HuCAL® phage display library, expressed in *E. coli*. The antibody is tagged with a DYKDDDDK tag and a double extended Strep-tag (SAWSHPQFEKGGGSGGGSSGSAWSHPQFEK). This antibody is supplied as a liquid.

### Preparation

StrepTactin affinity chromatography

### Buffer Solution

Phosphate buffered saline

### Preservative Stabilisers

0.01% Thiomersal

### Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

### Immunogen

Ipilimumab

### Specificity

**Human Anti-Ipilimumab Antibody, clone AbD34294** specifically recognizes the monoclonal antibody drug ipilimumab when in complex with its target, CTLA-4 (cytotoxic T-lymphocyte antigen-4). The antibody does not recognize free ipilimumab or unbound recombinant human CTLA-4. It can be used to measure levels of ipilimumab in patient samples.

Clone AbD34294 is a monovalent Fab format antibody that can be used to develop a

pharmacokinetic (PK) antigen capture assay to measure free ipilimumab captured via immobilized CTLA-4.

Ipilimumab (Yervoy) is a human IgG1/kappa antibody developed from a transgenic mouse. It has been approved by the FDA for the treatment of metastatic melanoma, renal cell carcinoma, and in combination with nivolumab for the treatment of previously treated microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) metastatic colorectal cancer. Ipilimumab activates the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. The action of cytotoxic T lymphocytes (CTLs) to recognize and destroy cancer cells is subject to an inhibitory mechanism that interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to function.

[View a summary of all anti-ipilimumab antibodies](#)

---

<b>Affinity</b>	The monovalent intrinsic affinity of AbD34294 was measured as $K_D = 252$ nM by real time, label free molecular interaction analysis on immobilized CTLA-4/ipilimumab complex.
<b>ELISA</b>	Clone AbD34294 is recommended for use as the detection reagent in an antigen capture assay to measure free ipilimumab captured via immobilized CTLA-4.  Protocol: <a href="#">PK antigen capture ELISA to measure bound drug exclusively</a>
<b>Storage</b>	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Yervoy is a trademark of Bristol-Myers Squibb Company.
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10094 available at: 10094: <a href="https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf">https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf</a>
<b>Licensed Use</b>	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
<b>Regulatory</b>	For research purposes only
<b>Technical Advice</b>	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <a href="#">HuCAL Antibodies Technical Manual</a>

---

## Related Products

### Recommended Secondary Antibodies

Rat Anti Synthetic Peptide DYKDDDDK TAG (MCA4764...) [HRP](#)

### Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HUMAN ANTI IPILIMUMAB \(HCA327\)](#)

[HUMAN ANTI IPILIMUMAB \(HCA328\)](#)

[HUMAN ANTI IPILIMUMAB \(HCA329\)](#)

[HUMAN ANTI IPILIMUMAB \(HCA330\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

'M373298:200909'

**Printed on 09 Sep 2020**

---

© 2020 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)